ABBV vs. SMMT: AbbVie vs. Summit Therapeutics Stock Comparison
How do AbbVie (ABBV) and Summit Therapeutics (SMMT) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
AbbVie (ABBV) and Summit Therapeutics (SMMT) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | ABBV | SMMT |
|---|---|---|
| Name | AbbVie Inc. | Summit Therapeutics Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 514.92 billion USD | 13.06 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | January 2, 2013 | March 5, 2015 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ABBV | SMMT |
|---|---|---|
| Total Return (1Y) | 37.33% | -2.48% |
| Total Return (3Y, Annualized) | 32.74% | 116.18% |
| Total Return (5Y, Annualized) | 24.73% | 26.89% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. AbbVie (ABBV) has a non-negative beta of 0.21.
| Metric | ABBV | SMMT |
|---|---|---|
| Volatility (1Y, Annualized) | 25.65% | 75.06% |
| Beta (5Y) | 0.21 | -1.51 |
| Max Drawdown (5Y) | -21.92% | -87.64% |
| Avg. Volume (3M) | 4.76M | 6.19M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ABBV | SMMT |
|---|---|---|
| Sharpe Ratio (1Y) | 1.29 | -0.09 |
| Sortino Ratio (1Y) | 2.02 | -0.13 |
Profitability
ROE (TTM)
AbbVie (ABBV) has no ROE value reported for this period; Summit Therapeutics (SMMT) reports a negative figure of -220.01%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- ABBV
- --
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
-220.01%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- SMMT
- -220.01%
Net Margin (TTM)
AbbVie (ABBV) at 15.67% retains a top-quartile share of revenue as profit, ahead of Summit Therapeutics (SMMT) at 0.00%, which keeps about the industry-typical share.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.67%
- Max
- 18.05%
- ABBV
- 15.67%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- SMMT
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
AbbVie (ABBV) at 39.59% operates in the top operating margin quartile, ahead of Summit Therapeutics (SMMT) at 0.00%, which runs around its industry’s norm.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
39.59%
- Max
- 83.12%
- ABBV
- 39.59%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 83.12%
- Q3
- 14.77%
- SMMT
- 0.00%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ABBV | SMMT |
|---|---|---|
| ROE (TTM) | -- | -220.01% |
| ROA (TTM) | 10.74% | -111.99% |
| Net Margin (TTM) | 15.67% | 0.00% |
| Operating Margin (TTM) | 39.59% | 0.00% |
| Gross Margin (TTM) | 73.72% | 0.00% |
Growth
Revenue Growth
Only one side can be read here: AbbVie (ABBV) reports revenue growth of 8.57%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.
EPS Growth
Only one side can be read here: AbbVie (ABBV) reports EPS growth of -0.84%, ranked against its industry; Summit Therapeutics (SMMT) has no EPS growth figure this period.
Growth Metrics
| Metric | ABBV | SMMT |
|---|---|---|
| Revenue Growth (YoY) | 8.57% | -- |
| Revenue Growth (3Y CAGR) | 1.75% | -- |
| EPS Growth (YoY) | -0.84% | -- |
| EPS Growth (3Y CAGR) | -29.03% | -- |
Financial Strength
Current Ratio (MRQ)
Summit Therapeutics (SMMT) at 5.99 keeps current ratio within its industry’s typical mid-range, while AbbVie (ABBV) at 0.87 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ABBV.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.87
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- ABBV
- 0.87
- Min
- 0.10
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.99
- Max
- 25.13
- Q3
- 12.13
- SMMT
- 5.99
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: Summit Therapeutics (SMMT) carries debt-to-equity ratio of 0.04 against its industry range, while AbbVie (ABBV) reports no figure this period.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- ABBV
- --
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.04
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- SMMT
- 0.04
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ABBV | SMMT |
|---|---|---|
| Current Ratio (MRQ) | 0.87 | 5.99 |
| Debt / Equity (MRQ) | -- | 0.04 |
| Net Debt / EBITDA | 2.21 | -- |
Dividends
Dividend Yield (TTM)
Summit Therapeutics (SMMT) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AbbVie (ABBV) reports a yield of 2.40%, ranking against industry peers normally.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.40%
- ABBV
- 2.40%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SMMT
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings; Summit Therapeutics (SMMT) pays no dividend (payout 0.00%).
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
117.35%
- ABBV
- 117.35%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SMMT
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ABBV | SMMT |
|---|---|---|
| Dividend Yield (TTM) | 2.40% | 0.00% |
| Dividend Payout Ratio (TTM) | 117.35% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: AbbVie (ABBV) trades at 50.05 times trailing earnings, ranked against its peers, while Summit Therapeutics (SMMT) has no P/E ratio this period.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
50.05
- Max
- 85.34
- ABBV
- 50.05
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- SMMT
- --
P/S Ratio (TTM)
A sales-based read is only available for AbbVie (ABBV), whose P/S ratio of 7.80 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.80
- Max
- 58.18
- Q3
- 25.77
- ABBV
- 7.80
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
- SMMT
- --
P/B Ratio (MRQ)
AbbVie (ABBV) reports a negative P/B ratio of -112.34, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Summit Therapeutics (SMMT) reports 23.13, ranking against industry peers normally.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
-112.34
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
- ABBV
- -112.34
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.13
- SMMT
- 23.13
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ABBV | SMMT |
|---|---|---|
| P/E Ratio (TTM) | 50.05 | -- |
| P/S Ratio (TTM) | 7.80 | -- |
| P/B Ratio (MRQ) | -112.34 | 23.13 |
| Free Cash Flow Yield (TTM) | 3.44% | -1.64% |